Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
mBio
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • Topics
    • Applied and Environmental Science
    • Clinical Science and Epidemiology
    • Ecological and Evolutionary Science
    • Host-Microbe Biology
    • Molecular Biology and Physiology
    • Therapeutics and Prevention
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About mBio
    • Editor in Chief
    • Board of Editors
    • AAM Fellows
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
Letter to the Editor

MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection

Ekaterina Marakasova, Ancha Baranova
Liise-anne Pirofski, Editor
Ekaterina Marakasova
aSchool of Systems Biology, George Mason University (GMU), Fairfax, Virginia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ancha Baranova
aSchool of Systems Biology, George Mason University (GMU), Fairfax, Virginia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liise-anne Pirofski
Albert Einstein College of Medicine
Roles: Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/mBio.03447-20
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

A recently published study by Jeffrey E. Gold et al. (1) presents data that strongly suggest that measles-mumps-rubella (MMR) vaccination negatively correlates with the severity of coronavirus disease 2019 (COVID-19)-related symptoms. Another study by Alba Grifoni et al. (2) demonstrated that antibody titers to spike protein in some unexposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subjects may reach substantial levels, thus suggesting preexisting immunity to the coronavirus. This preexisting immunity may be due to the cross-reactivity with other antigens, for example the ones resulting from previous immunizations. Other studies reported that COVID-19 mortality is higher in countries where Mycobacterium bovis BCG vaccination is not routinely administered (3). Why previously received MMR vaccine may aid in reducing the severity of coronavirus infection symptoms is not clear, but it is tempting to speculate that one or more of the MMR components may be structurally similar to SARS-CoV epitopes recognized by the immune system and may contribute to cross-immunity. Hence, we performed homology analysis between the receptor binding domain (RBD) of the spike protein and the nucleocapsid protein of SARS-CoV-2 to measles, mumps, and rubella proteomes using BLAST (4). A similarity between the RBD of the surface glycoprotein of COVID-causing coronavirus and the measles fusion glycoprotein (chain B) was evident (Fig. 1).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Structural characteristics of coronavirus surface glycoprotein and measles fusion glycoprotein. (A) Protein structure of coronavirus surface glycoprotein in complex with LCB1. The PDB accession no. 7JZU (12) was visualized by Chimera version 1.13.1 (13) and colored by secondary structure as follows: red, helix; purple, strand; gray, coil. (B) Protein structure of measles fusion glycoprotein (chain B). The PDB (5YXW [14]) for measles fusion glycoprotein was visualized by Chimera version 1.13.1 (13) and colored by secondary structure as follows: red, helix; purple, strand; gray, coil. (C) Aligned protein structures by Chimera version 1.13.1 (13). The coronavirus surface glycoprotein (7JZU [12]) (blue) and measles virus fusion glycoprotein chain B (5YXW [14]) (red) are shown. (D) Sequence comparison between coronavirus surface glycoprotein and measles virus fusion glycoprotein (chain B). Pairwise sequence analysis of coronavirus surface glycoprotein (NCBI accession no. YP_009724390.1) and measles fusion glycoprotein (5YXW_B) was performed by Emboss Needle version 6.6.0 (15). Abbreviations: C, coronavirus; M, measles. Full sequence identity: 93/1,393 (6.7%); # similarity: 152/1,393 (10.9%). Solvent accessibility for aligned sequences was calculated by RaptorX-Property (16) as follows: 45% exposed, 23% medium, and 30% buried for coronavirus surface glycoprotein and 41% exposed, 28% medium, and 30% buried for measles fusion glycoprotein (chain B).

The fusion protein of the measles virus is necessary for virus-cell membrane merging and subsequent injection of its ribonucleocapsid complex into the host cell cytosol. More specifically, in fusion glycoprotein (chain B) of attenuated strains of the measles virus of MMR vaccine interacts with the host cell surface receptors, including CD46 (5). Immunogenicity of the fusion glycoprotein is well-known, as it is reported as an effective target for serological responses (6). Similarly, coronavirus RBD is also recognized as an epitope for immune response (7). Our findings support the hypothesis that the chain B of the fusion protein of the measles virus may play a role in anti-SARS-CoV-2 immunological responses by its cross-reaction with RBD protein of the COVID-19-causing virus. An alternative explanation to the MMR-induced alleviation of coronavirus infection is that the RBD of coronaviral S protein may weakly engage the receptor for measles virus CD46, a complement regulatory molecule, also known as membrane cofactor protein MCP (8). It is tempting to speculate that anti-measles virus antibodies may bind SARS-CoV-2 in a way that prevents it from interacting with CD46 receptor, which normally protects the cells against complement-mediated cell lysis and, therefore, alleviates COVID-related abnormal activation of the complement posed in some recent studies (9–11). Notably, only attenuated measles vaccine strains recognize CD46, while wild-type disease-causing virus employs other entry (8), possibly explaining why the anti-COVID protective effects are detected after MMR vaccination but not as an aftermath of the natural measles disease (8). In our opinion, the findings described above warrant investigation.

FOOTNOTES

    • Published 2 February 2021
  • For the author reply, see https://doi.org/10.1128/mBio.03682-20.

  • Copyright © 2021 Marakasova and Baranova.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

REFERENCES

  1. 1.↵
    1. Gold JE,
    2. Baumgartl WH,
    3. Okyay RA,
    4. Licht WE,
    5. Fidel PL,
    6. Noverr MC,
    7. Tilley LP,
    8. Hurley DJ,
    9. Rada B,
    10. Ashford JW
    . 2020. Analysis of measles-mumps-rubella (MMR) titers of recovered COVID-19 patients. mBio 11:e02628-20. doi:10.1128/mBio.02628-20.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Grifoni A,
    2. Weiskopf D,
    3. Ramirez SI,
    4. Mateus J,
    5. Dan JM,
    6. Moderbacher CR,
    7. Rawlings SA,
    8. Sutherland A,
    9. Premkumar L,
    10. Jadi RS,
    11. Marrama D,
    12. de Silva AM,
    13. Frazier A,
    14. Carlin AF,
    15. Greenbaum JA,
    16. Peters B,
    17. Krammer F,
    18. Smith DM,
    19. Crotty S,
    20. Sette A
    . 2020. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181:1489–1501.e15. doi:10.1016/j.cell.2020.05.015.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Miyasaka M
    . 2020. Is BCG vaccination causally related to reduced COVID-19 mortality? EMBO Mol Med 12:e12661. doi:10.15252/emmm.202012661.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Zhang J,
    2. Madden TL
    . 1997. PowerBLAST: a new network BLAST application for interactive or automated sequence analysis and annotation. Genome Res 7:649–656. doi:10.1101/gr.7.6.649.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Plattet P,
    2. Alves L,
    3. Herren M,
    4. Aguilar HC
    . 2016. Measles virus fusion protein: structure, function and inhibition. Viruses 8:112. doi:10.3390/v8040112.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. El Mubarak HS,
    2. Ibrahim SA,
    3. Vos HW,
    4. Mukhtar MM,
    5. Mustafa OA,
    6. Wild TF,
    7. Osterhaus AD,
    8. de Swart RL
    . 2004. Measles virus protein-specific IgM, IgA, and IgG subclass responses during the acute and convalescent phase of infection. J Med Virol 72:290–298. doi:10.1002/jmv.10553.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Okba NMA,
    2. Müller MA,
    3. Li W,
    4. Wang C,
    5. GeurtsvanKessel CH,
    6. Corman VM,
    7. Lamers MM,
    8. Sikkema RS,
    9. de Bruin E,
    10. Chandler FD,
    11. Yazdanpanah Y,
    12. Le Hingrat Q,
    13. Descamps D,
    14. Houhou-Fidouh N,
    15. Reusken C,
    16. Bosch BJ,
    17. Drosten C,
    18. Koopmans MPG,
    19. Haagmans BL
    . 2020. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis 26:1478–1488. doi:10.3201/eid2607.200841.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Baldo A,
    2. Galanis E,
    3. Tangy F,
    4. Herman P
    . 2016. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Hum Vaccin Immunother 12:1102–1116. doi:10.1080/21645515.2015.1122146.
    OpenUrlCrossRef
  9. 9.↵
    1. Malaquias MAS,
    2. Gadotti AC,
    3. Motta-Junior JDS,
    4. Martins APC,
    5. Azevedo MLV,
    6. Benevides APK,
    7. Cézar-Neto P,
    8. Panini do Carmo LA,
    9. Zeni RC,
    10. Raboni SM,
    11. Fonseca AS,
    12. Machado-Souza C,
    13. Moreno-Amaral AN,
    14. de Noronha L
    . 2020. The role of the lectin pathway of the complement system in SARS-CoV-2 lung injury. Transl Res doi:10.1016/j.trsl.2020.11.008.
    OpenUrlCrossRef
  10. 10.↵
    1. Marcos-Jiménez A,
    2. Sánchez-Alonso S,
    3. Alcaraz-Serna A,
    4. Esparcia L,
    5. López-Sanz C,
    6. Sampedro-Núñez M,
    7. Mateu-Albero T,
    8. Sánchez-Cerrillo I,
    9. Martínez-Fleta P,
    10. Gabrie L,
    11. Guerola LDC,
    12. Rodríguez-Frade JM,
    13. Casasnovas JM,
    14. Reyburn HT,
    15. Valés-Gómez M,
    16. López-Trascasa M,
    17. Martín-Gayo E,
    18. Calzada MJ,
    19. Castañeda S,
    20. Fuente H,
    21. González-Álvaro I,
    22. Sánchez-Madrid F,
    23. Muñoz-Calleja C,
    24. Alfranca A
    . 2020. Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID-19 patients. Eur J Immunol doi:10.1002/eji.202048858.
    OpenUrlCrossRef
  11. 11.↵
    1. Tiwari R,
    2. Mishra AR,
    3. Mikaeloff F,
    4. Gupta S,
    5. Mirazimi A,
    6. Byrareddy SN,
    7. Neogi U,
    8. Nayak D
    . 2020. In silico and in vitro studies reveal complement system drives coagulation cascade in SARS-CoV-2 pathogenesis. Comput Struct Biotechnol J 18:3734–3744. doi:10.1016/j.csbj.2020.11.005.
    OpenUrlCrossRef
  12. 12.↵
    1. Cao L,
    2. Goreshnik I,
    3. Coventry B,
    4. Case JB,
    5. Miller L,
    6. Kozodoy L,
    7. Chen RE,
    8. Carter L,
    9. Walls AC,
    10. Park Y-J,
    11. Strauch E-M,
    12. Stewart L,
    13. Diamond MS,
    14. Veesler D,
    15. Baker D
    . 2020. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science 370:426–431. doi:10.1126/science.abd9909.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Pettersen EF,
    2. Goddard TD,
    3. Huang CC,
    4. Couch GS,
    5. Greenblatt DM,
    6. Meng EC,
    7. Ferrin TE
    . 2004. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25:1605–1612. doi:10.1002/jcc.20084.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Hashiguchi T,
    2. Fukuda Y,
    3. Matsuoka R,
    4. Kuroda D,
    5. Kubota M,
    6. Shirogane Y,
    7. Watanabe S,
    8. Tsumoto K,
    9. Kohda D,
    10. Plemper RK,
    11. Yanagi Y
    . 2018. Structures of the prefusion form of measles virus fusion protein in complex with inhibitors. Proc Natl Acad Sci U S A 115:2496–2501. doi:10.1073/pnas.1718957115.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Madeira F,
    2. Park YM,
    3. Lee J,
    4. Buso N,
    5. Gur T,
    6. Madhusoodanan N,
    7. Basutkar P,
    8. Tivey ARN,
    9. Potter SC,
    10. Finn RD,
    11. Lopez R
    . 2019. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res 47:W636–W641. doi:10.1093/nar/gkz268.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Wang S,
    2. Li W,
    3. Liu S,
    4. Xu J
    . 2016. RaptorX-Property: a web server for protein structure property prediction. Nucleic Acids Res 44:W430–W435. doi:10.1093/nar/gkw306.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Download PDF
Citation Tools
MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection
Ekaterina Marakasova, Ancha Baranova
mBio Feb 2021, 12 (1) e03447-20; DOI: 10.1128/mBio.03447-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this mBio article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection
(Your Name) has forwarded a page to you from mBio
(Your Name) thought you would be interested in this article in mBio.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection
Ekaterina Marakasova, Ancha Baranova
mBio Feb 2021, 12 (1) e03447-20; DOI: 10.1128/mBio.03447-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About mBio
  • Editor in Chief
  • Board of Editors
  • AAM Fellows
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Author Warranty
  • Article Types
  • Ethics
  • Contact Us

Follow #mBio

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Online ISSN: 2150-7511